PURPOSE: Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartan medoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obese rat (SHROB), a model of cardiometabolic syndrome. METHODS: Male SHROB were treated with vehicle or AZL-M orally for 56 days. Vehicle treated normotensive Wistar-Kyoto (WKY) rats served as controls. The effects of AZL-M on kidney injury, vascular endothelial and heart functions, lipid profile, and glucose tolerance were assessed. RESULTS: AZL-M demonstrated anti-hypertensive effects along with markedly improved vascular endothelial function in SHROB. In these rats, AZL-M demonstrates strong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB. CONCLUSION: Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.
PURPOSE: Angiotensin II type 1 receptor blockers (ARBs) are widely used in treating hypertension. In the present study, we tested the hypothesis that a novel ARB, azilsartanmedoxomil (AZL-M) will prevent renal and cardiovascular injury in the spontaneously hypertensive obeserat (SHROB), a model of cardiometabolic syndrome. METHODS: Male SHROB were treated with vehicle or AZL-M orally for 56 days. Vehicle treated normotensive Wistar-Kyoto (WKY) rats served as controls. The effects of AZL-M on kidney injury, vascular endothelial and heart functions, lipid profile, and glucose tolerance were assessed. RESULTS:AZL-M demonstrated anti-hypertensive effects along with markedly improved vascular endothelial function in SHROB. In these rats, AZL-M demonstrates strong kidney protective effects with lower albuminuria and nephrinuria along with reduced tubular cast formation and glomerular injury. AZL-M treatment also improved left ventricular heart function, attenuated development of left ventricular hypertrophy, and reduced cardiac fibrosis in SHROB. CONCLUSION: Overall, these findings demonstrate kidney and heart protective effects of AZL-M in SHROB, and these effects were associated with its ability to lower blood pressure and improve endothelial function.
Authors: Kasi C McPherson; Corbin A Shields; Bibek Poudel; Brianca Fizer; Alyssa Pennington; Ashley Szabo-Johnson; Willie L Thompson; Denise C Cornelius; Jan M Williams Journal: Am J Physiol Renal Physiol Date: 2018-12-12
Authors: Md Abdul Hye Khan; Lauren Kolb; Melissa Skibba; Markus Hartmann; René Blöcher; Ewgenij Proschak; John D Imig Journal: Diabetologia Date: 2018-07-21 Impact factor: 10.122
Authors: Fabiane Valentini Francisqueti; Igor Otávio Minatel; Artur Junio Togneri Ferron; Silméia Garcia Zanati Bazan; Vanessa Dos Santos Silva; Jéssica Leite Garcia; Dijon Henrique Salomé de Campos; Ana Lúcia Ferreira; Fernando Moreto; Antonio Carlos Cicogna; Camila Renata Corrêa Journal: Nutrients Date: 2017-11-29 Impact factor: 5.717
Authors: Md Abdul Hye Khan; Sung Hee Hwang; Scott D Barnett; Anna Stavniichuk; Wojciech K Jankiewicz; Bruce D Hammock; John D Imig Journal: Br J Pharmacol Date: 2021-08-12 Impact factor: 8.739